| Primary |
| Hypertension |
20.3% |
| Product Used For Unknown Indication |
11.5% |
| Atrial Fibrillation |
7.8% |
| Migraine |
7.8% |
| Depression |
6.3% |
| Anxiety |
3.6% |
| Basedow's Disease |
3.6% |
| Essential Tremor |
3.6% |
| Rash |
3.6% |
| Tremor |
3.6% |
| Anorexia |
3.1% |
| Arrhythmia |
3.1% |
| Hepatic Cirrhosis |
3.1% |
| Tachycardia |
3.1% |
| Ascites |
2.6% |
| Autonomic Nervous System Imbalance |
2.6% |
| Headache |
2.6% |
| Hyperthyroidism |
2.6% |
| Menopause |
2.6% |
| Portal Hypertension |
2.6% |
|
| Respiratory Arrest |
8.1% |
| Vomiting |
8.1% |
| Intentional Overdose |
7.1% |
| Suicide Attempt |
7.1% |
| Bradycardia |
6.1% |
| Drug Hypersensitivity |
5.1% |
| Sepsis |
5.1% |
| Shock |
5.1% |
| Syncope |
5.1% |
| Thrombocytopenia |
5.1% |
| Visual Impairment |
5.1% |
| Palpitations |
4.0% |
| Pyrexia |
4.0% |
| Tachycardia |
4.0% |
| Thrombotic Stroke |
4.0% |
| Tremor |
4.0% |
| Vertigo |
4.0% |
| Dizziness |
3.0% |
| Dyspnoea |
3.0% |
| Fatigue |
3.0% |
|
| Secondary |
| Migraine |
24.5% |
| Multiple Sclerosis |
18.6% |
| Product Used For Unknown Indication |
9.8% |
| Hypertension |
7.1% |
| Foetal Exposure During Pregnancy |
6.1% |
| Drug Use For Unknown Indication |
5.6% |
| Depression |
4.4% |
| Asthma |
3.7% |
| Anxiety |
3.5% |
| Emphysema |
2.8% |
| Bronchitis |
2.7% |
| Menopause |
2.2% |
| Tremor |
1.8% |
| Bipolar I Disorder |
1.4% |
| Schizophrenia |
1.3% |
| Parkinsonism |
1.0% |
| Ill-defined Disorder |
0.9% |
| Insomnia |
0.9% |
| Blood Cholesterol Increased |
0.8% |
| Diabetes Mellitus |
0.8% |
|
| Tremor |
12.1% |
| Drug Hypersensitivity |
9.9% |
| Toxicity To Various Agents |
7.7% |
| Vomiting |
7.7% |
| Weight Decreased |
6.6% |
| Loss Of Consciousness |
5.5% |
| Somnolence |
5.5% |
| Rash |
4.4% |
| Syncope |
4.4% |
| Vision Blurred |
4.4% |
| Weight Increased |
4.4% |
| Balance Disorder |
3.3% |
| Cleft Palate |
3.3% |
| Drug Screen Positive |
3.3% |
| Liver Disorder |
3.3% |
| Malaise |
3.3% |
| Palpitations |
3.3% |
| Presyncope |
3.3% |
| Atrioventricular Block Complete |
2.2% |
| Drug Ineffective |
2.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
20.3% |
| Drug Use For Unknown Indication |
13.0% |
| Hypertension |
11.6% |
| Depression |
6.4% |
| Migraine |
6.3% |
| Anxiety |
5.7% |
| Pain |
5.2% |
| Osteoporosis |
3.8% |
| Gastrooesophageal Reflux Disease |
2.9% |
| Rheumatoid Arthritis |
2.8% |
| Hypothyroidism |
2.4% |
| Hormone Replacement Therapy |
2.4% |
| Cardiac Disorder |
2.4% |
| Headache |
2.2% |
| Bipolar Disorder |
2.1% |
| Blood Cholesterol Increased |
2.1% |
| Diabetes Mellitus |
2.1% |
| Insomnia |
2.1% |
| Multiple Sclerosis |
2.0% |
| Hepatitis C |
2.0% |
|
| Weight Increased |
14.1% |
| Vomiting |
10.2% |
| Weight Decreased |
10.2% |
| Pulmonary Embolism |
5.8% |
| Nausea |
5.7% |
| Tremor |
5.5% |
| Pain |
5.3% |
| Urinary Tract Infection |
4.5% |
| Vision Blurred |
4.4% |
| Drug Ineffective |
4.0% |
| White Blood Cell Count Decreased |
3.8% |
| Rash |
3.3% |
| Pyrexia |
3.2% |
| Death |
3.1% |
| Myocardial Infarction |
3.1% |
| Headache |
3.0% |
| Type 2 Diabetes Mellitus |
3.0% |
| Oedema Peripheral |
2.9% |
| Transient Ischaemic Attack |
2.9% |
| Malaise |
2.3% |
|
| Interacting |
| Blood Pressure |
15.0% |
| Hypertension |
10.3% |
| Bone Pain |
8.4% |
| Osteoporosis |
7.5% |
| Emphysema |
5.6% |
| Intervertebral Disc Degeneration |
4.7% |
| Spinal Column Stenosis |
4.7% |
| Abdominal Discomfort |
3.7% |
| Anxiety |
3.7% |
| Atrial Fibrillation |
3.7% |
| Constipation |
3.7% |
| Dyslipidaemia |
3.7% |
| Dyspepsia |
3.7% |
| Gastrooesophageal Reflux Disease |
3.7% |
| Product Used For Unknown Indication |
3.7% |
| Toxic Nodular Goitre |
3.7% |
| Blood Cholesterol Increased |
2.8% |
| Mitral Valve Prolapse |
2.8% |
| Urinary Incontinence |
2.8% |
| Dementia Alzheimer's Type |
1.9% |
|
| Nausea |
20.0% |
| Respiratory Tract Congestion |
15.0% |
| Tremor |
15.0% |
| Drug Interaction |
10.0% |
| Obstructive Airways Disorder |
10.0% |
| Torsade De Pointes |
10.0% |
| Arrhythmia |
5.0% |
| Medication Error |
5.0% |
| Shock |
5.0% |
| Suicidal Ideation |
5.0% |
|
